Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic

Bibliography

• HOWARD HR, SHENK KD, SMOLAREK TA eta].: Synthesis of 3-H and 14-C-Labelled CP-88,059: A potent atypical antipsychotic agent. J. Labeled Compounds &Pharmaceu-ticals (1994) 34:117–125.
   Google Scholar
• PRAKASH C, KAMEL A, GUMMERUS J, WILNER K: Metabo-lism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos. 25(7)863–872.
   Google Scholar
• WILNER KD, DeMATTOS SB, ANZIANO RJ et al.: Lack of CYP2D6 inhibition by ziprasidone in healthy volunteers. Proceedings of the 151st Meeting of the American Psychiatric Association. Toronto, Canada (1998).
   Google Scholar
• PRAKASH C, KAMEL A, CUT D: Characterization of thenovel benzisothiazole ring-cleaved products of the antipsychotic drug ziprasidone. Drug Metab. Dispos. (1997) 25(7)897–901.
   Google Scholar
• WILNER K, SHERWOOD J, ANZIANO RJ, AWEEKA F:Pharmacokinetics of ziprasidone in normal and impaired renal function. Proceedings of the 151st Meeting of the American Psychiatric Association. Toronto, Canada (1998).
   Google Scholar
• HAMELIN BA, ALLARD S, LAPLANTE L et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsy-chotic agent ziprasidone. Pharmacotherapy (1998) 18(1) 9–15
   PubMed Web of Science ®Google Scholar
• SEEGER TF, SEYMOUR PA, SCHMIDT AW et al: Ziprasi- done (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. (1995) 275:101–113.
   PubMed Web of Science ®Google Scholar
• ••A complete review of ziprasidone's receptor activity andeffects in preclinical assays.
   Google Scholar
• ERNST AM: Mode of action of apomorphine and dexamphatamine on gnawing compulsion in rats. Psychopharmacology (1967) 10:316–323.
   PubMed Web of Science ®Google Scholar
• COSTALL B, NAYLOR RJ: Stereotyped and circling behavior induced by dopaminergic agonists after lesions of the midbrain raphe nuclei. Eur. J. Pharmacol (1974) 29:206–222.
   PubMed Web of Science ®Google Scholar
• NIEMEGEERS CJE, JANSSEN PAJ: A sytematic study of thepharmacological activities of dopamine antagonists. Life ScL (1979) 24:2201–2215.
   PubMed Web of Science ®Google Scholar
• ROBERTS DCS, ZIS AP, FIBIGER HC: Ascending catecho-lamine pathways and amphetamine-induced locomotor activity: importance of dopamine and apparent non-involvement of norepinephrine. Brain Res. (1975) 93:441–454.
   PubMed Web of Science ®Google Scholar
• LUCKI I, NOBLER MS, FRAZER A: Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J. Pharmacol Exp. Ther. (1984) 228:133–139.
   PubMed Web of Science ®Google Scholar
• COOK L, CATANIA C: Effects of drugs on avoidance and escape behavior. Fed. Proc. (1964) 23:818–835.
   PubMedGoogle Scholar
• SANBERG PR: Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature (1980) 284:472–473.
   PubMed Web of Science ®Google Scholar
• FISCHMAN AJ et al.: Positron emission tomographicanalysis of central 5-hydroxytryptamine 2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J. Pharmacol Exp. Ther. (1996) 279(2)939–947.
   Google Scholar
• •Determination of the time course of 5HT2 receptor occupancy of ziprasidone in healthy volunteers.
   Google Scholar
• BENCH CJ, LAMMERTSMA AA, GRASBY PM eta].: The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psycho-pharmacology (1996) 124:141–147.
   Google Scholar
• •Determination of the time course of central dopamine D2 receptor binding of ziprasidone in healthy volunteers.
   Google Scholar
• GOFF DC, POSEVER T, HERZ L et al: An exploratory haloperidol-controlled dose-finding study of ziprasi-done in hospitalized patients with schizophrenia or schizoaffective disorder. J. Clin. Psychopharmacol (1998) 18(4):296–304.
   PubMed Web of Science ®Google Scholar
• •Exploratory does-ranging trial which established a dose-response relationship among ziprasidone groups in CGI-S.
   Google Scholar
• KECK P, BUFFENSTEIN A, FERGUSON J et al. & THE ZIPRASIDONE STUDY GROUP: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial. Psychopharmacology (1998) 140(2):173–184.
   PubMed Web of Science ®Google Scholar
• ••Double-blind, placebo-controlled multicentre studyshowing ziprasidone 120 mg/day effective in the treatment of positive, negative and affective symptoms of schizo-phrenia and schizoaffective disorder.
   Google Scholar
• DANIEL DG, ZIMBROFF DL, POTKIN SG, REEVES KR, HARRIGAN EP, LAKSHMINARAYAN M: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial in the ziprasidone study group. Neuropsychopharmacology (1999) 20(5)491–505.
   Google Scholar
• ••Summary of the Phase III trial of two fixed doses of ziprasi-done supports the rapid improvement in psychotic symptoms using PANSS, BRSd total and CGI-I scales.
   Google Scholar
• ARATO M, 0-CONNOR R, BRADBURY JE, MELTZER H, FOR THE ZEUS STUDY GROUP: Ziprasidone and the long-term treatment of negative symptoms in preven-tion of exacerbation of schizophrenia. Proceedings of the 151st Meeting of the American Psychiatric Association. Toronto, Canada (1998).
   Google Scholar
• DANIEL DG, WEIDEN P, STERN S, BIRNBAUM R, KRAMER T: Switching to ziprasidone from conventional and novel antipsychotics: improvements in tolerability and health status measures in outpatients. Proceedings of the 1999 Annual Meeting of the American College of Neuropsychopharmacology. Acapulco, Mexico (1999).
   Google Scholar
• ALLISON DB, MENTORE JL, HEO M, WIDEN PJ, CAPPEL-LERI J, CHANDLER LP: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry (1999) 156(10:1686–1696.
   PubMedGoogle Scholar
• MICELI J, PERSKORN S, WILNER K, FOLGER C, TENSFELDT T: Use of population pharmacokinetic modeling to characterize the intramuscular pharmacokinetics of the novel antipsychotic agent ziprasidone in schizo-phrenic patients. Proceedings of the 151st Meeting of the American Psychiatric Association. Toronto, Canada (1998).
   Google Scholar
• BROOK S, KRAMS M, GUNN KP, THE ZIPRASIDONE IM STUDY GROUP: The efficacy and tolerability of intramuscular (IM) ziprasidone versus IM haloperidol in patients with acute, non-organic psychosis. Proceed-ings of the 151st Meeting of the American Psychiatric Association. Toronto, Canada (1998).
   Google Scholar
• SWIFT RH, HARRIGAN EP, CAPPELLERI JC, KRAMER D, CHANDLER LT: Validation of the behavioral activity rating scale (BARS): A novel measure of activity in agitated patients. Proceedings of the 151st Meeting of the American Psychiatric Association. Toronto, Canada (1998).
   Google Scholar
• SWIFT RH, HARRIGAN EP, van KAMMEN DP: A comparison of intramuscular (IM) ziprasidone with IM haloperidol. Proceedings of the 151st Meeting of the American Psychiatric Association. Toronto, Canada (1998).
   Google Scholar
• REEVES KR, SWIFT RH, HARRIGAN EP: Intramuscular ziprasidone 10 mg and 20 mg in patients with psychosis and acute agitation. Proceedings of the 151st Meeting of the American Psychiatric Association. Toronto, Canada (1998).
   Google Scholar